Page 2 of 102 | IMAGING IN PLASMA CELL DISORDERS (WB DW-MRI) have been extensively studied for monitor- ing response to therapy,8–10 and provided information com- plementary to traditional response assessment. The most recent iteration of response assessment guidelines by the International Myeloma Working Group (IMWG) has ac- knowledged imaging as an integral part of minimal residual disease...
See more from The Fellow on Call: The Heme/Onc Podcast
As ASCO23 approaches we all know there will be even more myeloma updates. Let’s not get lost in the essentials. This is a great review article on how to approach frequency of imaging in plasmacytoma, smoldering MM, and newly diagnosed MM.